The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
January 3rd 2025
A phase 3 trial highlights betibeglogene autotemcel as a potentially curative gene therapy for severe transfusion-dependent β-thalassemia.
Thirty-Day Readmissions: Relationship to Physician Attending Type and Social Connectedness
This study examined patient clinical and demographic characteristics, healthcare system factors, and patients’ experiences of care associated with 30-day readmissions in a hospital with a Pioneer Accountable Care Organization.
Read More
FDA Approves Trogarzo for Patients With Multidrug-Resistant HIV
March 7th 2018The FDA approved the antiretroviral medication for adult patients living with HIV who have been treated with multiple medications in the past and whose HIV infection did not respond to other currently available antiretroviral therapies.
Read More
Uber, Lyft Launch Efforts to Eliminate Transportation Barriers to Healthcare
March 7th 2018Last week, Uber introduced Uber Health, a service that allows hospitals, doctor’s offices, and other health systems to order an Uber for their patients. Yesterday, Allscripts announced a collaboration with Lyft to let clinicians to order the Lyft service for patients through its electronic health record system.
Read More
Pain Management in Cancer and the Risk of Patients Developing Opioid Use Disorder
March 3rd 2018As cancer treatments improve and death rates decline, more patients survive who are at risk of becoming addicted to pain medications they were prescribed to treat their cancer-related pain, explained Merrill Norton, PharmD, NCAC II, CCS, CCDP-D, of the University of Georgia.
Read More
Designing Best Practices to Better Manage Patients on Oral Cancer Medications
March 3rd 2018Positive quality interventions are part of a nationwide effort to standardize and improve oncology dispensing practices. They are best practices that are meant to be highly specific to a drug and help pharmacies and clinicians ensure that a patient-centric model exists, explained speakers during a workshop at National Community Oncology Dispensing Association (NCODA) Spring Forum 2018.
Read More
COPD More Prevalent in Rural Areas, CDC Analysis Finds
March 1st 2018State variations in chronic obstructive pulmonary disease (COPD) outcomes suggest that the condition is more common in large rural areas compared with metropolitan areas, according to the Morbidity and Mortality Weekly Report from CDC.
Read More
HCT Effective for Patients With Non-Hodgkin Lymphoma Regardless of Age
February 28th 2018New research has found that allogeneic hematopoietic stem cell transplantation is just as effective in patients with non-Hodgkin lymphoma who are age 65 and older as it is in patients between the ages of 55 and 64.
Read More
PFS Recommended as Primary End Point for Phase 2 Immune Checkpoint Inhibitor Trials
February 26th 2018Traditionally, objective response rate (ORR) is used as the primary end point for phase 2 trials assessing the efficacy of anticancer therapies. However, in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers, progression-free survival (PFS) is recommended as a primary end point over ORR, according to a study published in JAMA Oncology.
Read More
Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors
February 24th 2018Recent study results showed larotrectinib was effective in patients with tropomyosin receptor kinase fusion-positive cancer, regardless of the age of the patient or the tumor type. In addition to implications for the treatment of genetic alterations across tumor types, these study results underscore the importance of molecular profiling of tumors, through which patients were identified for the studies, on ensuring precision medicine is used in practice while simultaneously providing a cost-effective tool.
Read More
Informal Clinical Integration Associated With Lower Surgical Care Spending
February 23rd 2018With formal integration initiatives, such as accountable care organizations, having modest effects, researchers analyzed the impact of informal clinical integration on cardiac surgery payments and found that patients who were treated in health systems with higher informal integration had greater savings.
Read More
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
February 21st 2018CAR T-cell therapies tisagenlecleucel (Kymriah, Novartis) and axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead) may come with hefty price tags, but the cost-effectiveness of both therapies fell below or within commonly cited thresholds of $50,000 to $150,000 per quality-adjusted life years, according to a report by the Institute for Clinical and Economic Review.
Read More
What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies
February 21st 2018Research analyzes the cost of processing healthcare bills; supermarket operator Albertsons will buy drugstore chain Rite Aid; a review of phase 1 clinical trials finds just 1 in 10 children with cancer see improvements.
Read More
FDA Approves Apalutamide, First Treatment for Nonmetastatic Castration-Resistant Prostate Cancer
February 15th 2018FDA has approved apalutamide, the first treatment for nonmetastatic castration-resistant prostate cancer, based on results from a phase 3 study that showed the drug reduced the risk of metastasis or death by 72% and improved median metastasis-free survival by more than 2 years.
Read More
What We're Reading: $1B Medicare Lawsuit; Healthcare as a Right; Alzheimer Drug Trial Ends
February 14th 2018The Department of Justice is moving forward with a $1 billion lawsuit against UnitedHealth Group over Medicare claims; Oregon's legislature is considering adding healthcare as a right to the state's constitution; another trial for an Alzheimer disease drug is stopped.
Read More
The addition of daratumumab to standard-of-care regimens used to treat multiple myeloma, such as bortezomib, melphalan, and prednisone, decreased the risk of disease progression or death in newly diagnosed patients who were ineligible for autologous stem-cell transplantation.
Read More
Patients With COPD Face High Risk of Adverse Drug Reactions Due to Multimorbidity
February 10th 2018Multimorbidity is common in patients with chronic obstructive pulmonary disease (COPD), and is associated with high levels of polypharmacy, which can lead to an increased risk of adverse drug reactions.
Read More
CD4 Cell Counts Increased, Severe Immunodeficiency Decreased From 2002-2015
February 8th 2018From 2002 to 2015, CD4 cell counts at the start of combination antiretroviral therapy (cART) increased, and the proportion of individuals with severe immunodeficiency at the start of cART decreased among all income groups, according to a study published in Clinical Infectious Diseases.
Read More
Atezolizumab Treatment Safe and Effective in Metastatic Urothelial Cancer Patients
February 8th 2018Patients with metastatic urothelial cancer treated with atezolizumab monotherapy demonstrated tolerability for the drug and general ability to manage adverse effects, according to a study published in JAMA Oncology.
Read More
Genetic Testing a Must for Relatives of Cardiomyopathy Patients
February 5th 2018With 4 in 10 cardiomyopathies having genetic links, there is a need for relatives of patients with cardiomyopathy to be screened in order to prevent early death, according to a recent study published in European Heart Journal.
Read More
What We're Reading: State Insurance Mandates; Universal Flu Vaccine; Fla. Opioid Bills
February 5th 2018At least 9 states are considering their own health insurance mandates now that Congress has repealed that of the Affordable Care Act; a senator is calling on the United States to invest $1 billion into developing a universal flu vaccine; physicians believe proposed Florida legislation may be too tough on opioid prescriptions.
Read More
Dr Mark Fendrick: How Expensive Therapies Fit Into VBID for Oncology
January 29th 2018When a drug becomes first-line, I would like to think that as a clinician I would have access to that, but most importantly that my patients would not have to have a bake sale or take out a second mortgage on their homes to get therapies that are designed specifically for them, said A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan.
Watch